Go Pro
OTCMKTS:ADDXF

Addex Therapeutics (ADDXF) Stock Price, News & Analysis

Addex Therapeutics logo
$0.99 0.00 (0.00%)
As of 02/3/2023

About Addex Therapeutics Stock (OTCMKTS:ADDXF)

Key Stats

Today's Range
$0.99
$0.99
50-Day Range
$0.99
$0.99
52-Week Range
$0.99
$0.99
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Addex Therapeutics Ltd is a clinical‐stage biopharmaceutical company headquartered in Geneva, Switzerland, specializing in the discovery and development of small molecule allosteric modulators of G protein‐coupled receptors (GPCRs). The company’s research focuses primarily on metabotropic glutamate (mGlu) receptors, which play key roles in central nervous system disorders. By targeting allosteric sites on these receptors, Addex aims to achieve greater selectivity and safety compared with traditional orthosteric ligands.

The company’s lead clinical program, dipraglurant, is a negative allosteric modulator of the mGlu5 receptor being evaluated for levodopa‐induced dyskinesia in Parkinson’s disease. In parallel, Addex is advancing mGlu2 and mGlu3 receptor modulators for indications such as anxiety, depression and schizophrenia. These programs leverage the potential of allosteric modulation to fine‐tune receptor response rather than fully block or activate the receptor, which may reduce off‐target effects and improve therapeutic outcomes.

Founded in 2002 as a spin‐out from the University of Geneva, Addex has built a research and development infrastructure that spans Switzerland and the United States, with additional collaborations in Europe and North America. Over the years, the company has entered into strategic partnerships and license agreements with leading pharmaceutical firms to advance its pipeline. These collaborations have helped validate Addex’s proprietary technology and expand the reach of its investigational therapies.

Under the leadership of Chief Executive Officer Pierluigi Paracchi, Addex Therapeutics continues to leverage its expertise in GPCR allosteric modulation to address unmet medical needs in neurology and psychiatry. The company maintains a lean operating model focused on progression of its clinical candidates through key regulatory milestones, while exploring out‐licensing and co‐development opportunities to broaden the impact of its innovative drug discovery platform.

AI Generated. May Contain Errors.

Receive ADDXF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ADDXF Stock News Headlines

The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
Addex Therapeutics Reports Q3 2025 Financial Results
See More Headlines

ADDXF Stock Analysis - Frequently Asked Questions

Addex Therapeutics' stock was trading at $0.99 at the beginning of 2026. Since then, ADDXF shares have increased by 0.0% and is now trading at $0.99.

Shares of ADDXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
8/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:ADDXF
CIK
N/A
Fax
N/A
Employees
26
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.25
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (OTCMKTS:ADDXF) was last updated on 8/17/2026 by MarketBeat.com Staff.
From Our Partners